Nanoparticles offer new hope for treating alcohol-related liver disease
Across the world, more than 1.5 billion people suffer from chronic liver disease. The U.S. Centers for Disease…
Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third…
AI toolset reveals links between lung fibrosis and aging
A new research paper was published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled “AI-driven toolset for…
Antibody Treatment Could Block Gut-Derived Toxin Behind Kidney Fibrosis
A newly identified bacterial molecule called corisin appears to travel from the gut to the kidneys, triggering inflammation…
CHI3L1 emerges as a powerful biomarker for liver disease diagnosis and management
The identification of Chitinase-3-like protein 1 (CHI3L1) as a crucial biomarker in liver disease is revolutionizing how clinicians…
Kiwi family move to Australia to get cystic fibrosis drug Trikafta for daughter
Adalyn Delaney was suffering the effects of CF before she was even born, with health staff discovering during…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…